All posts by: Michael Zand

Speedy EU, US review for Novartis’ CAR–T therapy Kymriah
PharmaTimes
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR–T therapy Kymriah as a treatment for some patients with elapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). In the US, the Food and Drug …
Novartis’s Kymriah wins speedy reviews in US, EuropeWHTC
Novartis granted US FDA Priority Review for Kymriah™ (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCLMarkets Insider

all 8 news articles »